IN8bio Inc
INAB
Company Profile
Business description
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Contact
350 5th Avenue
Suite 5330
New YorkNY10118
USAT: +1 646 600-6438
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
A broad assessment of AI’s threats and opportunities leads to moat ratings changes for more than three dozen companies.
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
We’ve also lowered our fair value estimate of Baidu stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,924.20 | 83.70 | 0.95% |
| CAC 40 | 8,006.39 | 91.03 | 1.15% |
| DAX 40 | 23,829.75 | 420.38 | 1.80% |
| Dow JONES (US) | 47,740.80 | 239.25 | 0.50% |
| FTSE 100 | 10,376.35 | 126.83 | 1.24% |
| HKSE | 25,959.90 | 202.61 | 0.79% |
| NASDAQ | 22,695.95 | 308.27 | 1.38% |
| Nikkei 225 | 54,248.39 | 1,372.45 | -2.47% |
| NZX 50 Index | 13,094.37 | 523.52 | -3.84% |
| S&P 500 | 6,795.99 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,692.60 | 90.30 | 1.05% |
| SSE Composite Index | 4,123.14 | 26.54 | 0.65% |